Table S3. Details of neoadjuvant chemotherapy post LCRT (n=96).
| Characteristics | n (% where applicable) |
|---|---|
| Reasons for neoadjuvant chemotherapy | |
| Persistent radiological CRM positivity | 78 (81.3) |
| Organ infiltration requiring extended resection | 6 (6.3) |
| Interim chemotherapy | 9 (9.4) |
| Threatened radiological CRM | 3 (3.0) |
| Regimens used as neoadjuvant | |
| mFOLFIRINOX | 54 (56.3) |
| CAPOX | 42 (43.7) |
| Median number of chemotherapy doses | 4 [1–8] |
| Data available for grade 3 and grade 4 toxicities | 78 (81.3) |
| Individual toxicities | |
| Vomiting | 2 (2.6) |
| Oral mucositis | 2 (2.6) |
| Diarrhoea | 14 (17.9) |
| HFS (grade 2 and grade 3) | 6 (6.3) |
| Neutropenia | 14 (17.9) |
| Febrile neutropenia | 5 (6.4) |
| Anemia | 2 (2.6) |
| Non-neutropenic infections | 3 (3.8) |
| Fatigue (grade 3) | 2 (2.6) |
| Peripheral neuropathy (grade 3) | 4 (5.1) |
| Clinico-radiological response rates | |
| Complete response | 0 |
| Partial response | 35 (36.4) |
| Stable disease | 45 (46.9) |
| Progressive disease | 8 (8.3) |
| Not available | 8 (8.3) |
| Curative intent local resection post neoadjuvant chemotherapy | |
| Yes | 55 (57.3) |
| No | 41 (42.7) |
LCRT, long course chemoradiotherapy; CRM, circumferential margin; HFS, hand-foot syndrome; mFOLFIRINOX, modified 5 fluorouracil-leucovorin-irinotecan-oxaliplatin; CAPOX, capecitabine-oxaliplatin.